AR013569A1 - Nueva formulacion mejorada para el tratamiento de la tromboembolia - Google Patents

Nueva formulacion mejorada para el tratamiento de la tromboembolia

Info

Publication number
AR013569A1
AR013569A1 ARP970102135A ARP970102135A AR013569A1 AR 013569 A1 AR013569 A1 AR 013569A1 AR P970102135 A ARP970102135 A AR P970102135A AR P970102135 A ARP970102135 A AR P970102135A AR 013569 A1 AR013569 A1 AR 013569A1
Authority
AR
Argentina
Prior art keywords
treatment
tromboembolia
formulation
new improved
improved formulation
Prior art date
Application number
ARP970102135A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of AR013569A1 publication Critical patent/AR013569A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una novedosa formulacion farmacéutica que comprende el inhibidor de la trombina HOOC-CH2-(R)-Cgl-Aze-Pab en combinacion con glicéridosde cadena mediana. Un proceso para la preparacion de tal formulacion farmacéutica,el uso de dicha formulacion en eltratamiento de la tromboembolia, asi como un método para tratar un paciente que requiere dicho tratamiento mediante el uso de dichaformulacion.
ARP970102135A 1996-05-31 1997-05-20 Nueva formulacion mejorada para el tratamiento de la tromboembolia AR013569A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9602145A SE9602145D0 (sv) 1996-05-31 1996-05-31 New improved formulation for treatment of thromboembolism

Publications (1)

Publication Number Publication Date
AR013569A1 true AR013569A1 (es) 2001-01-10

Family

ID=20402816

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102135A AR013569A1 (es) 1996-05-31 1997-05-20 Nueva formulacion mejorada para el tratamiento de la tromboembolia

Country Status (14)

Country Link
US (1) US6673365B1 (es)
EP (1) EP1015022B1 (es)
JP (1) JP2000511526A (es)
AR (1) AR013569A1 (es)
AT (1) ATE284706T1 (es)
AU (1) AU722450B2 (es)
CA (1) CA2253410A1 (es)
DE (1) DE69731981T2 (es)
ID (1) ID19472A (es)
NO (1) NO985558L (es)
NZ (1) NZ332788A (es)
SE (1) SE9602145D0 (es)
WO (1) WO1997045138A1 (es)
ZA (1) ZA974386B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0203349D0 (sv) * 2002-11-12 2002-11-12 Astrazeneca Ab New use
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464175A (en) * 1982-08-25 1984-08-07 Altman Alan R Multipurpose tamponade and thrombosclerotherapy tube
US4568545A (en) * 1982-10-02 1986-02-04 Amano Seiyaku Kabushiki Kaisha Thrombolytic agent
CA2145763A1 (en) * 1992-10-02 1994-04-14 William J. Curatolo Pharmaceutical compositions containing nonionic surfactants
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation

Also Published As

Publication number Publication date
ATE284706T1 (de) 2005-01-15
ID19472A (id) 1998-07-16
JP2000511526A (ja) 2000-09-05
CA2253410A1 (en) 1997-12-04
SE9602145D0 (sv) 1996-05-31
AU722450B2 (en) 2000-08-03
WO1997045138A1 (en) 1997-12-04
NZ332788A (en) 2000-05-26
DE69731981D1 (de) 2005-01-20
DE69731981T2 (de) 2005-12-22
ZA974386B (en) 1997-12-01
NO985558D0 (no) 1998-11-27
EP1015022B1 (en) 2004-12-15
EP1015022A1 (en) 2000-07-05
NO985558L (no) 1998-11-27
US6673365B1 (en) 2004-01-06
AU3111597A (en) 1998-01-05

Similar Documents

Publication Publication Date Title
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
AR002254A1 (es) Formulacion antitrombotica y procedimiento para su manufactura
IS2130B (is) Glútamín-þíasólidíð og -pýrrólidíð og notkun þeirra sem dípeptidýlpeptíðasa IV hindrar
EA199800667A1 (ru) Новые фенантридины
GB9818916D0 (en) Use
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
ATE333896T1 (de) Vaskularisierungsinhibitoren
ES2178851T3 (es) Procedimiento para el tratamiento de un articulo que contienen un compuesto organico oxidable.
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
CO4820418A1 (es) Metodo para el tratamiento de substratos y activacion de blanqueadores
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
AR013569A1 (es) Nueva formulacion mejorada para el tratamiento de la tromboembolia
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
ATE215941T1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
NO970185L (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
AR031404A1 (es) Una composicion y metodo de aplicacion
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
ES2183205T3 (es) Hcg y derivados en calidad de inhibidores de melaloproteasas de la matriz.
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
AR039827A1 (es) Metodo para tratar la esclerosis multiple

Legal Events

Date Code Title Description
FA Abandonment or withdrawal